Abstract 102P
Background
In view of a higher likelihood of risk of having advanced adenoma or invasive cancer in the individual with above average, we investigated whether receiving subsequent faecal immunochemical tests (FITs) in the intervals between colonoscopies could reduce the risk of colorectal cancer (CRC) and advanced colorectal neoplasia (ACN) incidence.
Methods
A retrospective cohort study was performed among high-risk population for CRC between January 2012 and December 2022, in Tianjin, China. The incidence of CRC and ACN were calculated for the FIT surveillance and non-FIT surveillance groups and reported as the number of events per 100000 person-years. Cox proportional hazards model models were applied to evaluate the risks of CRC and ACN, with crude and adjusted hazard ratios (HRs) and 95% confidence intervals (CI).
Results
We included 12515 participants with a high risk of CRC, aged 40-74 years, of whom 4980 received subsequent FIT between colonoscopies during the study period. Among these participants, 51 CRC cases occurred in the non-FIT surveillance group (incidence rate, 233.88 per 100000 person-years) and there were 29 cases of CRC in the FIT surveillance group (incidence rate, 184.85 per 100000 person-years). The cumulative events of the advanced adenoma group were highest, followed by the non-advanced adenoma group, then the no neoplasia group stratified based on the prior colonoscopy findings. Compared with the non-FIT surveillance group, the FIT surveillance group had a 54% decreased risk of developing CRC (HR, 0.46; 95% CI, 0.29-0.74) and a 45% decreased risk of developing ACN (HR, 0.55; 95% CI, 0.47-0.64).
Conclusions
In this CRC surveillance program, our study found that high-risk participants who received subsequent FIT surveillance in the intervals between colonoscopy were associated with a reduction of CRC and ACN incidence, which indicated the value and utility of FIT in the surveillance program.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
This work was supported by the National Natural Science Foundation of China (Grant. No: 81973135 and 81972826) and Science and Technology Commission of Shanghai Municipality (Grant. No: 21XD1402600).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
298P - Managing locally advanced cervical cancer: Insights from a tertiary care center and a 3-year follow-up on outcomes
Presenter: Ambedkar Yadala
Session: Poster Display
Resources:
Abstract
299P - Sexual dysfunction assessment in longterm survivors of carcinoma cervix using LENT SOMA scale
Presenter: Niharika Sethi
Session: Poster Display
Resources:
Abstract
300P - Assessing ovarian function in Vietnamese cervical cancer patients who underwent ovary transposition prior to pelvic radiation therapy
Presenter: Cuong Nguyen
Session: Poster Display
Resources:
Abstract
301P - Correlation between cervical cancer recurrence after radiation therapy and vaginal microbiome
Presenter: Xiaoxian Xu
Session: Poster Display
Resources:
Abstract
302P - Expression of ERCC4 gene and its correlation with clinical and pathological parameters in cervical cancer
Presenter: Himanshu Mishra
Session: Poster Display
Resources:
Abstract
303P - Prognostic value of body composition and systemic inflammatory markers in patients with locally advanced cervical cancer following chemoradiotherapy
Presenter: Hui Guo
Session: Poster Display
Resources:
Abstract
305P - A real-world multicenter cohort study of lenvatinib (LEN) plus pembrolizumab (PEM) in Japanese patients with endometrial cancer: Interim analysis of GOGO-EM4 study
Presenter: Yoshikazu Nagase
Session: Poster Display
Resources:
Abstract
306P - Adjuvant treatment and impact on relapse in stage IA uterine papillary serous and clear cell carcinomas: A single center retrospective study
Presenter: Sachin Khurana
Session: Poster Display
Resources:
Abstract
307P - Hormonal therapy vs combination chemotherapy in metastatic leiomyosarcomas: A systematic review
Presenter: Patricia Angel
Session: Poster Display
Resources:
Abstract
309P - Expression of estrogen receptor is a negative predictive biomarker for immunotherapy with lenvatinib plus pembrolizumab for advanced endometrial cancer with pMMR
Presenter: Hiroyuki Fujii
Session: Poster Display
Resources:
Abstract